John H. Zhang

Yan Qu

Weijian Jiang

Wengui Yu

Zhongsong Shi

Benyan Luo

This volume is focused on subjects related to cerebral ischemia and reperfusion injuries after acute stroke. All chapters are selected from the Sixth Elite Stroke meeting named Pangu Stroke Conference and written by members of world leading laboratories of stroke studies. The contents cover both clinical and bench studies, from basic components of cerebral arterial system to clinical reperfusion injury cases, from reperfusion caused programmed cell death and astrocyte activation to oxidative stress and nitric oxide after reperfusion, from extracellular matrix and inflammation to a role of diabetes after reperfusion, from small artery disorders to collateral circulation and blood pressure control after reperfusion. Wei-Jian Jiang, Chairman of New Era Stroke Care and Research Institute of PLA Rocket Force General Hospital, Beijing, China. Wengui Yu, Professor and Director of Comprehensive Stroke & Cerebrovascular Center, University of California, Irvine Yan Qu, Professor and Director of Neurosurgery at the Second Affiliated Hospital of Air Force Medical University, Xi’an, China. Zhongsong Shi, Professor of Neurosurgery at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Ben-yan Luo, Professor and Chair of Neurology at the First Affiliated Hospital of Zhejiang University. John H. Zhang, Professor of Anesthesiology and Physiology at Loma Linda University School of Medicine, Loma Linda, CA, USA.

Bench Research and Clinical Implications

Cerebral Ischemic Reperfusion Injuries (CIRI)

Jeffrey M. Gidday

Miguel A. Perez-Pinzon

Cerebral preconditioning is a phenomenon wherein a mild insult or stress induces cellular and tissue adaptation or tolerance to a later, severe injury, therefore reflecting the efficacy of endogenous mechanisms of cerebrovascular protection. Initially identified for rapid cardiac protection, preconditioning has expanded to all aspects of CNS protection from ischemia, trauma and potentially neurodegeneration. Many different stimuli or stressors have been identified as preconditioning agents, suggesting a downstream convergence of mechanisms and underscoring the potential for translational application of preconditioning in the clinic. Moreover, the fundamental mechanisms responsible for preconditioning-induced tolerance will help in the design novel pharmacological approaches for neuroprotection. While stroke and many other brain injuries are not predictable, in some populations (e.g., metabolic syndrome, patients undergoing carotid endarterectomy, aneurysm clipping, or with recent TIAs) the risk for stroke is identifiable and significant, and preconditioning may represent a useful strategy for neuroprotection. For unpredictable injuries, post-conditioning the brain – or inducing endogenous protective mechanisms after the initial injury – can also abrogate the extent of injury. Finally, remote pre- and post-conditioning methods have been developed in animals, and are now being tested in clinical trials, wherein a brief, noninjurious stress to a noncerebral tissue (i.e., skeletal muscle) can provide protection to the CNS and thereby allows clinicians the opportunity to circumvent concerns regarding the direct preconditioning of neurological tissues.

Translational Neuroprotection by Pre- and Post-Conditioning

Innate Tolerance in the CNS

Jun Chen

Xiaoming Hu

This book provides a comprehensive overview of the latest research in the role of non-neuronal cells - astrocytes, oligodendrocytes, endothelial cells, pericytes, microglia, and other immune cells in ischemic brain injury and long-term recovery. In these cases, neurodegeneration and brain repair are controlled in a sophisticated system, incorporating interactions between different cell types and cellular systems. Also explored are the therapeutic strategies that target non-neuronal responses after stroke and their translational potentials.

Non-Neuronal Mechanisms of Brain Damage and Repair After Stroke

Louis R. Caplan

José Biller

Eng H. Lo

Megan C. Leary

Ajith J Thomas

Midori Yenari

Primer on Cerebrovascular Diseases, Second Edition, is a handy reference source for scientists, students, and physicians needing reliable, up-to-date information on basic mechanisms, physiology, pathophysiology, and medical issues related to brain vasculature. The book consists of short, specific chapters written by international experts on cerebral vasculature, presenting the information in a comprehensive and easily accessible manner. Numerous changes have occurred in the field since the publication of the first edition in 1997, particularly our understanding of the genetic aspects of cerebrovascular disease. This updated edition reflects the advances made over the last two decades, not only demonstrating the promise for therapy, but also for a molecular understanding of cerebrovascular diseases. The new edition includes new and expanded topics, including carotid stenting, Iatrogenic causes of stroke, axonal transport and injury, RNAIs, proteomics, and more. Provides concise chapters on topics in cerebral blood flow and metabolism, pathogenesis of cerebrovascular disorders, diagnostic testing, and management in a comprehensive and accessible format Written by international leading authorities on cerebral vasculature Provides up-to-date information on practical applications of basic research and the main clinical issues facing the community, such as axonal transport and proteomics

Primer on Cerebrovascular Diseases

Jian Wang

Ling Wei

The blood-brain-barrier serves to encapsulate and protect the central nervous system, but it also presents a major barricade to therapeutic drug delivery. Poor penetration is the most common hurdle to translating a promising experimental therapy that uses invasive delivery methods to a clinically useful application. In the last 10 years, intranasal delivery of various therapeutic compounds including small chemicals, large proteins, and even stem cells has proven to be very effective in bypassing the blood-brain-barrier and has led to some important advances in translational research for stroke and other neurological diseases. The proposed book will bring together reports from various labs around the world who have had successes in pre-clinical studies of intranasal therapies for various diseases including adult and perinatal stroke, Alzheimer's, Parkinson's, and others.​

Therapeutic Intranasal Delivery for Stroke and Neurological Disorders

Gang Chen

Richard L. Applegate

Hua Feng

In this book, leading world authorities on brain edema and neurological disorders/injuries and experts in preconditioning join forces to discuss the latest progress in basic sciences, translational research, and clinical management strategies relating to these conditions. The range of topics covered is wide, including microglia, energy metabolism, trace metals and ion channels, vascular biology, cellular treatment, hemorrhagic stroke, novel technological advances, anesthesia and medical gases, pediatric brain edema, neuroimaging, behavioral assessment, clinical trials, peripheral to central signaling pathways, preconditioning translation, and animal models for preconditioning and brain edema research. The book comprises presentations from Brain Edema 2014, the joint meeting of the 16th International Conference on Brain Edema and Cellular Injury and the 3rd Symposium on Preconditioning for Neurological Disorders, held in Los Angeles on September 27–30, 2014.

Translate Basic Science into Clinical Practice

Brain Edema XVI

Paul A. Lapchak

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research. The emphasis is placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.

From Target Selection to Clinical Trials

Translational Stroke Research

Robert D. Martin

Warren Boling

This book highlights the latest developments in acute and delayed neurovascular injury studies including delayed cerebral vasospasm, early brain injury, micro-circulation compromise, spreading cortical depolarization, neuroinflammation, and long-term cognitive dysfunctions after subarachnoid hemorrhage. About 32 chapters cover original presentations from the 14th international conference on neurovascular events after subarachnoid hemorrhage, held in Los Angeles in October 2017. Neurosurgeons, neurologists, and neuro-ICU practitioners discuss clinical observations, new pilot treatments, clinical trials, academic and industrial interactions, including surgical and endovascular approaches, brain injury monitoring, new developments in brain imaging, ICU management, early brain injury scales and management, counter cortical depolarization management and anti-inflammation management. In addition, animal models used to study acute and delayed neurovascular events, the basic mechanisms of vascular, neuronal, and CSF physiology, new experimental treatment strategies, new frontiers in the treatment of neurovascular injuries, and new research directions are discussed.

Neurological Care and Protection

Subarachnoid Hemorrhage

Yang V. Li

Stroke is a major cause of death and disability in the U.S. and worldwide. A variety of pathophysiologic episodes or cellular medications occur following a stroke, and knowledge of these aftermath events can lead to potential therapeutic strategies that may reverse or attenuate stroke injury. Cellular events that occur following stroke include the excessive releases of excitatory amino acids, alterations in the genomic responses, mitochondrial injury producing reactive oxygen and nitrogen species (ROS), and secondary injury, often in the setting of reperfusion.

Metal Ion in Stroke

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

Neuroprotective Therapy for Stroke and Ischemic Disease

John H. Zhang

About

Books

Join the club